Drugs prompting the most divergent opinions on outlook include Pfizer and Vir’s Covid-19 offerings and Biogen’s Aduhelm.
Bayer’s drug shows a benefit in less severe chronic kidney disease patients in Figaro-DKD.
Lilly and Novo look set for a battle in glucose-sensitive insulin, and other areas too.
Novo moves into amyloidosis not long after Intellia made a splash here.
After a patient develops inhibitors questions emerge about a new approach to treating haemophilia A.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.